BIBLIOGRAFÍA
1. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS et al.Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
2. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous lowdosetherapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
3. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomiccyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-48.
4. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108:804-11.
5. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006; 214:229-38.
6. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36.
7. Gille J, Spieth K, Kaufmann R. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges 2005; 3:26-32.
8. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23:939-52.
9. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005; 65:7045-51.
10. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F et al. Low-dose oralmethotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13:73-80.
11. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006; 17:961-67.
12. Krajnak S, Battista MJ, Hasenburg A, Schmidt M. Metronomic Chemotherapy for Metastatic Breast Cancer. Oncol Res Treat. 2022;45(1-2):12-17. doi:10.1159/00 052 0236. Epub 2021 Nov 18. PMID: 34794154.
13. Mutsaers AJ. Metronomic chemotherapy. Top Companion Anim Med. 2009 Aug;24(3):137-43. doi: 10.1053/j.tcam.2009.03.004. PMID: 19732732.
14. Cazzaniga ME, Dionisio MR, Riva F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett. 2017 Aug 1;400:252-258. doi: 10.1016/ j.canlet.2016.12.019. Epub 2016 Dec 23. PMID: 28017894.
15. Woo IS, Jung YH. Metronomic chemotherapy in metastatic colorectal cancer. Cancer Lett. 2017 Aug 1;400:319-324. doi: 10.1016/j.canlet.2017.02.034. Epub 2017 Mar 6. PMID: 28274890.
16. Bandini A, Calabrò PF, Banchi M, Orlandi P, Bocci G. Metronomic Chemotherapy in Elderly Patients. Curr Oncol Rep. 2024 Apr;26(4):359-376. doi:10.1007/ s11912-024-01505-w. Epub 2024 Mar 7. PMID: 38448722; PMCID: PMC11021319.
17. Caparica R, De Angelis C, Fêde Â, Werutsky G, de Azambuja E. Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?Expert Rev Anticancer Ther. 2020 Jul;20(7):563-573. doi: 10.1080/ 14737140.2020.1782200. Epub 2020 Jun 30. PMID: 32536212.
18. De Felice F, Benevento I, Musella A, Musio D, Tombolini V. Metronomic chemotherapy in head and neck cancer. Cancer Lett. 2017 Aug 1;400:219-222. doi:10.1016/j.canlet.2016.10.047. Epub 2016 Nov 8. PMID: 27832971.
19. Noronha V, Krishna MV, Patil V, Joshi A, Banavali SD, Prabhash K. Metronomic therapy: chemotherapy revisited. Indian J Cancer. 2013 Apr-Jun;50(2):142-8. doi:10.4103/019-509X.117027. PMID: 23979206.
20. Fares JE, El Tomb P, Khalil LE, Atwani RW, Moukadem HA, Awada A, El Saghir NS. Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics. Cancer Treat Rev. 2020 Sep;89:102066. doi: 10.1016/j.ctrv.2020.102066. Epub 2020 Jun 29. PMID: 32769038.
21. Garg V, Kumar L. Metronomic chemotherapy in ovarian cancer. Cancer Lett. 2023 Nov 28;579:216469. doi: 10.1016/j.canlet.2023.216469. Epub 2023 Nov 3. PMID: 37923056.
22. André N, Tsai K, Carré M, Pasquier E. Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all? Trends Cancer. 2017 May;3(5):319-325. doi: 10.1016/j.trecan.2017.03.011. Epub 2017 Apr 21. PMID: 28718409.
23. Biziota E, Mavroeidis L, Hatzimichael E, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2017 Aug 1;400:243-251. doi: 10.1016 /j.canlet.2016.12.018. Epub 2016 Dec 23. PMID: 28017892.
24. Sarmiento R, Gasparini G. Antiangiogenic metronomic chemotherapy. Onkologie.2008 Apr;31(4):161-2. doi: 10.1159/000119925. Epub 2008 Mar 20. PMID: 18418015.
25. Bravetti G, Falvo P, Talarico G, Orecchioni S, Bertolini F. Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors. Cancer Lett. 2023 Nov 28;577:216441. doi:10.1016/j.canlet.2023.216441. Epub 2023 Oct 6. PMID: 37806515.
26. Chen YP, Shen JY, Deng ZJ, Sun Y, Liang XY, Lv JW, Ma J. Low-dose metronomicchemotherapy improves tumor control in nasopharyngeal carcinoma. Cancer Commun (Lond). 2022 Oct;42(10):909-912. doi: 10.1002/cac2.12347. Epub 2022 Aug 4. PMID:35924896; PMCID: PMC9558682.
27. Twu CW, Lin PJ, Tsou HH, Liu YC, Jiang RS, Liang KL, Lin TY, Wang WY, Lin JC. Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma. Head Neck. 2022 Jun;44(6):1453-1461. doi: 10.1002/hed.27044. Epub 2022 Apr 1. PMID: 35362634.
28. Riesco-Martinez M, Parra K, Saluja R, Francia G, Emmenegger U. Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett. 2017 Aug 1;400:311-318. doi: 10.1016/j.canlet.2017.02.027. Epub 2017 Mar 1. PMID: 28259819; PMCID: PMC5555746.
29. Wu HL, Zhou HX, Chen LM, Wang SS. Metronomic chemotherapy in cancer treatment: new wine in an old bottle. Theranostics. 2024 Jun 1;14(9):3548-3564. doi: 10.7150/thno.95619. PMID: 38948068; PMCID: PMC11209710.
30. Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, Marchetti P. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol. 2013 Jul;72(1):13-33. doi: 10.1007/s00280-013-2125-x. Epub 2013 Mar 9. PMID: 23475105.
31. Liu J, He M, Wang Z, Li Q, Xu B. Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer. Oncol Res Treat. 2022;45(11):681-692. doi: 10.1159/000526481. Epub 2022 Aug 19. PMID: 35988534;PMCID: PMC9677858.
32. Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016 Nov;13(11):659-673. doi: 10.1038/nrclinonc.2016.64. Epub 2016 May 17. PMID: 27184418.
33. Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015 Mar 28;358(2):100-106. doi: 10.1016/j.canlet.2014.12.039. Epub 2014 Dec 23. PMID:25541061; PMCID: PMC4666022.
